The biological sequelae of PDA has been partially attributed to frequent and well characterized mutations in *KRAS* (\>90%), *CDKN2A* (\>90%), *TP53* (70%) and *SMAD4* (55%)^[@R1]--[@R4]^. Recent genome-wide analyses have uncovered numerous additional somatic genetic alterations, although the functional relevance of most remains uncertain^[@R5]^. To explore the molecular genesis of PDA we previously generated a mouse model of Pancreatic Intraepithelial Neoplasia (mPanIN) by conditionally expressing an endogenous *Kras^G12D^* allele in the developing pancreas^[@R8]^. Mice with mPanIN spontaneously progress to mouse PDA (mPDA) after a long and variable latency, providing an opportunity to characterize genes that cooperate with *Kras^G12D^* to promote early mPDA. We hypothesized that such genes could be directly identified by applying insertional mutagenesis strategies^[@R6],[@R7],[@R10],[@R11]^ in our mPanIN model, and that these candidates could represent "drivers" of PDA development.

Accordingly, we interbred our mPanIN model with two distinct *Sleeping Beauty* (SB) transposon systems and monitored mice for early disease progression. Our initial approach utilized the well characterized *CAGGS-SB10* transgenic allele to promote transposition^[@R6]^. Although *CAGGS-SB10* promoted PDA, a variety of non-pancreatic neoplasms and a paucity of identified Common Insertion Sites (CISs) in the recovered pancreatic neoplasms precluded a comprehensive analysis, potentially reflecting the variegated expression of *CAGGS-SB10*^[@R12]^ ([Supplementary Figures 1a and 2](#SD1){ref-type="supplementary-material"}; [Supplementary Tables 1 and 3b](#SD2){ref-type="supplementary-material"}).

To increase the specificity and potency of SB mutagenesis, we generated a conditional *SB13* mutant mouse by targeting the *Rosa26* locus in embryonic stem cells ([Supplementary Fig. 3a, b](#SD1){ref-type="supplementary-material"}). The pancreatic specific expression and function of the conditional *SB13* allele was confirmed ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}), and we found that *SB13*-induced transposition by itself did not promote lethality or pancreatic tumorigenesis ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). In contrast, KCTSB13 mice (*Kras^LSL-G12D^*; *Pdx1-cre; T2/Onc; Rosa26-LSL-SB13*) rapidly progressed and succumbed to invasive pancreatic neoplasms ([Fig. 1a--c](#F1){ref-type="fig"}). A cohort of 117 KCTSB13 mice ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}) was monitored for tumor development, and 103 of these mice were available for full necropsy and tissue procurement. The majority of such mice harbored multi-focal pancreatic tumors, and 198 distinct primary tumors and metastases were subjected to histological and molecular analysis. Most mice had invasive carcinomas (66/103) that consisted of classical mPDA (78.8%) or invasive cystic neoplasms (21.2%); 34.8% of mice also contained metastases predominantly in their liver and lungs ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). The remainder of the mice (37/103) had preinvasive pancreatic tumors consisting of high grade mPanIN and cyst-forming papillary neoplasms ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}).

The candidate genes identified from the SB13 screen represented unanticipated candidates as well as many genes and pathways previously implicated in human PDA ([Table 1](#T1){ref-type="table"}, [Supplementary Tables 2, 3a and 4](#SD2){ref-type="supplementary-material"}). Indeed, various members of the TGFβ pathway, including *Smad3*, *Smad4*, *Tgfbr1* and *Tgfbr2,* were collectively mutated in 32% of the tumors. Also, the Rb/p16Ink4a pathway was disrupted in 21% of the tumors. CISs representing the orthologues of additional human PDA genes included *Fbxw7* (24.2%), *Arid1a* (19.1%), *Acvr1b* (19%), *Stk11/Lkb1* (6.5 %), *Mll3* (6%), *Smarca4* (6%) and *Pbrm1* (4.5%)^[@R5],[@R13]--[@R15]^. *Trp53* was the only commonly mutated PDA gene conspicuously absent, although the p53 regulatory deubiquitinase Usp7 was a CIS (6.5%)^[@R16]^. Several CISs previously noted in insertional mutagenesis screens for hepatocellular carcinoma or gastrointestinal tract adenomas, but not typically mutated in PDA, were also identified in this study, including *Zbtb20*, *Nfib* and *Ube2h* in liver tumors^[@R10]^; and *Pten, Tcf12, Ppp1r12a, and Ankrd11* in gastrointestinal tract adenoma/adenocarcinoma^[@R11]^. This indicates that many tumor progression pathways may be common to pancreatic, liver and gastrointestinal/colorectal tumors.

Unexpectedly, the most frequent CIS observed was the X-linked deubiquitinase *Usp9x*, a gene that had not been previously associated with PDA or other types of carcinoma in humans or mouse models. Indeed, the COSMIC data base revealed only one *USP9X* mutation in a case of ovarian cancer, although the functional relevance of this mutation has not been characterized (COSMIC mutation ID: 73237). *Usp9x* was disrupted in over 50% of all tumors, with 341 insertions noted in the 101 tumors harboring this CIS ([Fig. 1d](#F1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}). Furthermore, *Usp9x* was also identified as a CIS in 4 samples from the initial SB10 screen ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}), supporting its candidacy as a PDA genetic determinant. We confirmed that *Usp9x* was disrupted in tumors by isolating chimeric fusion mRNAs that spliced the *Usp9x* transcript to the T2/Onc transposon ([Fig. 1e](#F1){ref-type="fig"}). In addition, the Usp9x protein was specifically absent in neoplastic cells in pancreatic tumors bearing intragenic insertions ([Fig. 1f, g](#F1){ref-type="fig"}).

To characterize the cellular and molecular pathways affected by *Usp9x* in PDA, RNAi was used to deplete *Usp9x* in mPDA cell lines ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). While Usp9x depletion did not affect the proliferation of monolayer cultures ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}), it significantly increased colony formation in soft agar ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Fig. 5c](#SD1){ref-type="supplementary-material"}), compared to cells transfected with scrambled shRNAs. Additionally, *Usp9x* knock-down potently suppressed anoikis in mPDA cells ([Fig. 2b](#F2){ref-type="fig"}). These properties of Usp9x were predominantly dependent upon its intrinsic deubiquitinase activity ([Supplementary Fig. 6a, b](#SD1){ref-type="supplementary-material"}).

Since USP9X was previously reported to positively regulate SMAD4 transcriptional activity^[@R17]^ and S*MAD4* is commonly mutated in PDA^[@R4]^, we hypothesized that *Usp9x* loss would attenuate Smad4 function or TGFβ responsiveness in PDA cell lines. However, irrespective of Usp9x expression level, mPDA cell lines expressed Smad4 and were equally sensitive to p21 induction, growth inhibition and morphological alterations following exposure to TGF-β1 ([Supplementary Fig. 7a--d](#SD1){ref-type="supplementary-material"}). Therefore we were unable to ascribe a specific role to Usp9x in the regulation of the Smad4/TGFβ pathway in mPDA cells or tumors.

We next investigated several additional proteins reported to be regulated by Usp9x and involved in pathways relevant to cellular transformation. Although USP9X was previously shown to bind to and regulate two proteins involved in cell survival, ASK1^[@R18]^ and MCL1^[@R9],[@R19]^, we could not detect obvious changes in Ask1 or Mcl1 protein levels upon *Usp9x* loss ([Fig. 2c](#F2){ref-type="fig"}). Usp9x has also been reported to deubiquitinate and thereby stabilize the E3 ligase Itch^[@R20]^, decreased protein levels of Itch were observed in mouse and human PDA cells upon the depletion of Usp9x ([Fig. 2c](#F2){ref-type="fig"}, [Supplementary Fig. 8a](#SD1){ref-type="supplementary-material"}). Importantly, ectopic Itch expression was sufficient to promote anoikis in mPDA cells ([Fig. 2d](#F2){ref-type="fig"}), and Itch was partially responsible for the ability of Usp9x to promote anoikis and suppress colony formation ([Supplementary Fig. 6c, d](#SD1){ref-type="supplementary-material"}). Since Itch is known to promote the degradation of several proteins relevant to cell proliferation and survival^[@R21]^, we evaluated the protein expression of likely candidates including c-Jun, p63 and c-FLIP but observed no alterations ([Supplementary Fig. 8b](#SD1){ref-type="supplementary-material"}). Furthermore, the *Itch* gene was identified as a CIS in 13% of cases ([Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Therefore, Usp9x mutation may promote tumorigenesis in part by disabling Itch function, and the Usp9x/Itch pathway may work to constrain pancreatic tumorigenesis.

To determine whether *USP9X* expression is aberrant in human PDA, three distinct patient cohorts were assessed. First, we analyzed a cohort of 100 Australian patients who underwent surgery for localized PDA and had detailed information available concerning clinical-pathological characteristics and outcome ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}, [Supplementary Tables 5, 6](#SD2){ref-type="supplementary-material"}). Tumor DNA from 88 patients in this cohort failed to yield somatic mutations in USP9X, consistent with prior reports^[@R5]^ (data not shown). Importantly, the low expression of *USP9X* mRNA correlated with poor survival following surgery (p=0.0076) ([Fig. 3a](#F3){ref-type="fig"}), and multivariate analysis revealed that *USP9X* expression was an independent poor prognostic factor following surgery ([Supplementary Table 7](#SD2){ref-type="supplementary-material"}). We next analyzed autopsy specimens from a separate cohort of 42 American patients to determine that USP9X protein expression inversely correlated with a widespread metastatic pattern (p=0.0212) ([Fig. 3b](#F3){ref-type="fig"}), and bore no relation to SMAD4 expression ([Supplementary Table 8](#SD2){ref-type="supplementary-material"}). A third collection of PDA specimens obtained from resected German patients (n=404) were used to determine that USP9X and ITCH protein levels were decreased ([Supplementary Fig. 10a, b](#SD1){ref-type="supplementary-material"}) and concordant (Spearman-Rho correlation: 0.47; p\<0.01) ([Supplementary Table 9a](#SD2){ref-type="supplementary-material"}) in tumors compared to normal pancreatic tissue. Additionally, the proportion of tumors that had undetectable USP9X (13.6%) or ITCH (30.5%) protein correlated with a worse outcome ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}, [Supplementary Table 9b, c](#SD2){ref-type="supplementary-material"}), particularly regarding USP9X in the subset of high grade tumors ([Fig. 3c](#F3){ref-type="fig"}, [Supplementary Tables 10 and 11](#SD2){ref-type="supplementary-material"}). Collectively, these findings implicate the loss of USP9X expression as a relevant event in human pancreatic cancer progression.

We found that USP9X was expressed throughout murine and human tumor development and lost focally in PDAs ([Supplementary Figures 12, 13](#SD1){ref-type="supplementary-material"}). Additionally, human PDA cell lines expressed lower levels of USP9X compared to non-PDA cancer cell lines ([Supplementary Fig. 14](#SD1){ref-type="supplementary-material"}). To investigate additional potential mechanisms of *USP9X* regulation in PDA, human cell lines were treated with the DNA methylase inhibitor 5-Aza-2′-deoxycytidine and the HDAC inhibitor trichostatin A. Both inhibitors modestly increased the USP9X mRNA and protein levels in most cell lines, suggesting that *USP9X* may be epigenetically silenced *in vivo* ([Fig. 3d](#F3){ref-type="fig"} and [Supplementary Fig. 15](#SD1){ref-type="supplementary-material"}). Furthermore, although the promoter region of USP9X was not heavily methylated in tumor samples or PDA cells harboring low protein expression (data not shown), treatment with 5-Aza-2′-deoxycytidine did decrease colony formation of human PDA cells and this was partially reversed by concomitantly knocking-down USP9X ([Supplementary Fig. 16](#SD1){ref-type="supplementary-material"}).

To confirm that *Kras^G12D^* cooperated with *Usp9x* loss to promote pancreatic cancer, a conditional *Usp9x^fl^*allele was generated ([Supplementary Fig. 17a](#SD1){ref-type="supplementary-material"}) and interbred with *Kras^LSL-G12D^; Pdx1-cre* mice to evaluate the impact on mPanIN progression. The mosaic expression of *Usp9x* in pancreas from *Pdx1-cre; Usp9x^fl/y^* mice was confirmed by immunohistochemistry ([Supplementary Fig. 17b](#SD1){ref-type="supplementary-material"}). We found that all hemizygous male mice and heterozygous female mice carriers of the *Usp9x^fl^* allele in the background of *Kras^LSL-G12D^; Pdx1-cre* rapidly developed advanced mPanIN and microinvasive neoplasms within 3 months of age ([Fig. 3e--f](#F3){ref-type="fig"}, [Supplementary Fig. 18](#SD1){ref-type="supplementary-material"}). Immunohistochemical analysis of mPanINs from heterozygous female mice demonstrated absence of Usp9x expression in the preneoplastic and neoplastic cells ([Supplementary Fig. 18](#SD1){ref-type="supplementary-material"}), implicating additional events such as X inactivation of the other locus in female mice^[@R22],[@R23]^. mPanINs in *Kras^LSL-G12D^; Pdx1-cre; Usp9x^fl^* mice expressed intranuclear Smad4, similar to *Kras^LSL-G12D^; Pdx1-cre* mice ([Supplementary Fig. 19a](#SD1){ref-type="supplementary-material"}). Additionally, early passage pancreatic cell cultures prepared from these mice confirmed the absence of the Usp9x protein and altered regulation of Itch ([Supplementary Fig. 19b](#SD1){ref-type="supplementary-material"}). Although some mice died of local or metastatic pancreatic cancer, aggressive oral papillomas often required the culling of young mice and demonstrated that *Kras^G12D^* and *Usp9x* loss also cooperated to transform keratinocytes ([Supplementary Fig. 19c](#SD1){ref-type="supplementary-material"}).

Although a recent report implicated *USP9X* as a pro-survival gene by stabilizing MCL1^[@R9]^, potential inhibitors of USP9X should be developed with caution since we find that *Usp9x* has tissue specific effects including a tumor suppressor role in oncogenic *Kras*-initiated pancreatic carcinoma. *USP9X* is likely epigenetically silenced in a subset of PDA, thus explaining why prior DNA sequencing efforts have failed to identify this as participant in carcinogenesis, and offering the possibility that clinically available epigenome modulators may be useful agents to investigate in such patients. ITCH is a likely mediator of pancreatic tumor suppression by USP9X, and continued investigation of the USP9X/ITCH pathway is warranted. More generally, the identification of *Usp9x* through the use of transposon mutagenesis reaffirms the utility of *in vivo* mouse cancer screens to complement the direct investigation of human cancer.

Methods Summary {#S1}
===============

*Kras^LSL-G12D^*(K)^24^, *Pdx1-Cre*^8^ (C), *T2/Onc*^6^ (T), *CAGGS-SB10*^6^ (SB10) and *Rosa26-LSL-SB13* (SB13) strains were interbred to generate *Kras^LSL-G12D^; Pdx1-Cre* (KC), *Kras^LSL-G12D^; Pdx1-Cre; T2/Onc; CAGGS-SB10* (KCTSB10) and *Kras^LSL-G12D^*; *Pdx-1-Cre*; T2/Onc; *Rosa26-LSL-SB13* (KCTSB13) compound mutant mice. Non-quadruple mutant mice represented the comparison cohorts. *Kras^LSL-G12D^* and *Pdx1-Cre* mice were interbred with *Usp9x^fl^* mice to generate the *Kras^LSL-G12D^; Pdx1-Cre; Usp9x^fl/+^* and *Kras^LSL-G12D^; Pdx1-Cre; Usp9x^fl/y^* (KCU) compound mutant mice, as well as the two control cohorts *Pdx1-cre; Usp9x^fl/y^* (CU) and *Kras^LSL-G12D^; Pdx1-cre* (KC). *Usp9x^fl^* mice were generated by Ozgene Pty. Ltd (Bentley, Australia). Mice were maintained in compliance with the UK home office regulations. Splinkerette PCRs were performed as described previously^[@R25],[@R26]^. Reads from sequenced tumors were mapped to the mouse genome assembly NCBI m37 and merged together to identify SB insertion sites, as previously described^[@R25]^. Redundant sequences, as well as insertions in the En2 gene and in the T2/Onc donor concatemer resident chromosome (chromosome 1), were removed. Mouse survival curves and cell culture experiments were analyzed with the GraphPad prism program. The IHC histoscoring from the TMA samples and Kaplan-Meier survival curves were analyzed with SPSS18, and the Spearman-Rho correlation coefficient (2-sided) between USP9X and ITCH was calculated. The IHC USP9X histoscore and analysis was conducted using the Fishers Exact Test on post-mortem samples. The GEO accession number for the ICGC-APGI gene expression data is GSE36924.

Methods {#S2}
=======

Generation of *Rosa26-LSL-SB13* knockin mice {#S3}
--------------------------------------------

TL1 ES cells^[@R27]^ were electroporated with linearized pRosa26-LSL-SA-SB13-BGHpolyA targeting construct and correctly targeted puromycin-resistant clones were identified by Southern blot. Two positives clones exhibiting a normal karyotype were used to generate chimeric mice by microinjection into C57BL/6 blastocysts. Germline transmission of the targeted allele was confirmed by Southern blot analysis of tail DNA from the agouti offspring.

T2/Onc excision PCR {#S4}
-------------------

Genomic DNAs were obtained from *Pdx1-cre; T2/Onc; Rosa26-LSL-SB13* (CTSB13) and *T2/Onc; Rosa26-LSL-SB13* (TSB13) mice and primers used to assess the excision of the T2/Onc concatemer in the CTSB13 mice were: 5′-TGTGCTGCAAGGCGATTA-3′ and 5′-ACCATGATTACGCCAAGC-3′.

CIS analysis {#S5}
------------

For the statistical analysis, 90,007 non-redundant insertion sites ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}) were used to identify CISs using a Gaussian Kernel Convolution framework (GKC)^[@R28]^. An enhanced version of the framework was developed for SB screens to account for the local density of TA sites within the genome^[@R25]^. For example, a genomic region containing a large number of insertion sites but a low density of TA sites is considered to be significant and thereby identified as a candidate CIS. Conversely, a region with a large number of insertion sites but also containing a high density of TA sites is determined to be less significant, since the transposons have more "target" sites into which they can integrate. Multiple kernel scales were employed in the GKC framework (widths of 15K, 30K, 50K, 75K, 120K and 240K nucleotides). CISs predicted across multiple scales and overlapping in their genomic locations were clustered together, such that the CIS with the smallest genomic "footprint" was reported as the representative CIS. For highly significant CISs with narrow spatial distributions of insertion sites, the 15K kernel is typically the scale on which CISs are identified. Additional statistical analysis of insertion sites was performed using a Monte Carlo framework^[@R10]^. CISs were compared to previously published datasets of human pancreatic cancer genetics^[@R5],[@R29],[@R30]^.

Detection of *Usp9x-T2/Onc* fusion mRNA by RT-PCR in SB tumors {#S6}
--------------------------------------------------------------

Total RNA was extracted from snap-frozen SB tumors using the RNeasy Mini Kit (Qiagen), and total RNA (1 μg) was reverse transcribed into cDNA using the High Capacity RNA-to-cDNA Kit (Applied Biosystems). RT--PCR was carried out with a nested PCR approach using primers of mouse *Usp9x* exon 1 and the Carp-β-Actin splice acceptor sequence of the T2/Onc transposon cassette. cDNA was used as a template in a first round of PCR using specific primers corresponding to exon 1 of *Usp9x* (5-gagtctgcgctgccgctgctg-3′) and Carp-β-Actin splice acceptor sequence (5′-cataccggctacgttgctaa-3′). The product of this reaction was used as a template in a second round of nested PCR using an internal primer in the *Usp9x* exon 1 (5′-gctgccgctgctgttgctgc-3′) and a second primer in the Carp-β-Actin splice acceptor sequence (5′-acgttgctaacaaccagtgc-3′). PCR products were cloned into pCR 2.1-TOPO vector (Invitrogen) and positives clones sequenced.

Plasmids, shRNAs and transfections {#S7}
----------------------------------

pSuperRetro-PURO retroviral vector (Oligoengine) expressed a short hairpin against mouse and human *USP9x* (5′-gatgaggaacctgcatttc-3′), mouse Itch (5′-gacctgagaagacgtttgt-3′)^[@R31]^, and a scramble sequence (5′-gcgcgctttgtaggattcg-3′). pBabe-zeo-Ecotropic Receptor (ecoR) was obtained from Addgene (plasmid\#10687). Myc-mItch cDNA was released from pCINeo-myc-Itch (Addgene plasmid\#11427), and was subcloned in the retroviral vector pBabe-neo (Addgene plasmid\#1767). KCU1 and KCU2 cell lines were transfected with pEF-DEST51-mUsp9x(WT)-V5 and pEF-DEST51-mUsp9x(C1566S)-V5 plasmids^[@R32],[@R33]^. The plasmid pEF/GW-51/LacZ (Invitrogen) was used as control. Transfections were done using Lipofectamine 2000 (Invitrogen). 24 hours later, cells were selected with 5 μg/ml blasticidin (Invitrogen).

Cell culture {#S8}
------------

Tumor pancreatic cancer cell lines were established from *Kras^LSL-G12D^; Pdx1-cre* (T4878 and T9394), *Kras^LSL-G12D^; P48-cre* (TB1572) and *Kras^LSL-G12D^; Pdx-1-Cre; Usp9x^fl^* (KCU1 and KCU2) mice as described previously^[@R34]^. Cells were subsequently cultured in DMEM (Invitrogen), supplemented with 10% FCS (Hyclone). The normal human pancreatic ductal cell line HPDE was generously provided by Dr. Tsao and cultured as described previously^[@R35],[@R36]^. The human pancreatic cancer cell lines AsPC1 (CRL-1682) and BxPC3 (CRL-1687) were acquired from ATCC and cultured according to instructions. The other cell lines were obtained from Clare Hall Laboratories (CRUK). The human cell lines Panc1, MiaPaCa2, 818.4, Hs766T, PATU2, SUIT2, FA6 and MDA-Panc3 (PDA); CaCO2 and SW1116 (colorectal cancer); SKBR3 (breast cancer) and A549 (lung cancer) were cultured in DMEM supplemented with 10% FCS. The human cell lines U937 (histiocytic lymphoma); RAMOS (Burkitt's lymphoma); NCI-H2179 (lung cancer) and ZR75-1 (breast cancer) were cultured in RPMI (Invitrogen) supplemented with 10% FCS. Cells were treated with 1 μM trichostatin A (Sigma) for 24 hours or with 5 μM 5-Aza-2′-deoxycytidine (Sigma) for 96 hours where indicated to obtain RNA and protein lysates to assess USP9x expression. For anchorage-independent growth assay, cells were treated with 5 μM 5-Aza-2′-deoxycytidine (Sigma).

Retroviral infections {#S9}
---------------------

Phoenix cells were plated 24 hr before transfection using the ProFection Mammalian Transfection System Calcium Phosphate (Promega). Target cells were infected with retroviruses produced in the Phoenix packaging cells (24 and 48 hr after transfection) in the presence of 8 μg/ml polybrene (Sigma) and were selected with 2 μg/ml puromycin (Sigma) or 1 mg/ml G418 (Clontech). Experiments were performed using at least 2 independent cell line infected pools. Human PDA cells lines Panc1, SUIT2 and PATU2 infected with retroviral vectors expressed the Ecotropic Receptor (ecoR).

Transformation, Anoikis and EMT assays {#S10}
--------------------------------------

Cell lines (1.5×10^4^ cells) were plated in triplicate in 12-well plates and counted as indicated using a Z2 Coulter (Beckman). Cells were fed every other day. Anchorage-independent growth assay was assessed by colony formation in soft agar. Briefly, 15,000 cells were plated in duplicates in DMEM with 15% serum and 0.34% low--melting point agarose (LMP, BioGene) onto 6-cm dishes coated with 0.5% LMP. Cells were fed twice a week and grown for 2 weeks. For the anoikis assay, 10^5^ cells/0.5 ml were plated in 24 well ultra low cluster plates (Costar) to allow them to grow in suspension for 4 days. Cells were harvested, washed with cold PBS and protein lysates were obtained. Cell line T4878 was cultured in matrigel as previously described^[@R37]^, plating 1000 cells/well. Cells were fed every 2 days and grown for 4 days. Epithelial-to-Mesenchymal Transition (EMT) was determined by plating 10^5^ cells/6 well plates for 24 hr to allow attachment, followed by treatment with human TGF-β1 (5 ng/ml) (RD Systems) for 24 hr. p21 induction was assessed after treatment with human TGF-β1 (5 ng/ml) (RD Systems) for 2 hr.

Real-time PCR {#S11}
-------------

Total RNA from human PDA cell lines was extracted using the Rneasy Mini Kit (Qiagen), and total RNA (1 μg) was reverse transcribed into cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems). Human *USP9x* expression was analyzed by quantitative PCR (q-PCR) using TaqMan gene expressiom assays Hs00245009_m1 (Applied Biosystems) on a 7900HT Real-Time PCR system (Applied Biosystems). Gene expression was normalized to human *β-ACTIN* expression, assessed with the gene expression assays Hs99999903_m1 (Applied Biosystems), and shown relative to control samples.

Western blot analysis {#S12}
---------------------

Cells were washed three times in cold PBS and lysed with boiling lysis buffer (1% SDS; 10mM, pH 7.5 Tris; 50mM NaF; 1mM Na~3~VO~4~). Lysates were boiled 5 minutes, passed through a 26 gauge needle to shear genomic DNA and centrifuged for 10 minutes at 14,000 rpm. Equivalent amounts of protein were resolved in 4--12% gradient SDS-PAGE gels (Invitrogen), transferred to Immobilon--P Transfer Membranes (Millipore), and incubated with the corresponding antibodies including anti-Ask1 (NB110-55482, Novus Biologicals); anti-Mcl1 (5453, Cell Signaling); anti-Usp9x (A301-351A, Bethyl); anti-CC3 (9664, Cell Signaling); anti-Itch (611198, BD); anti-p21 (sc-6246, Santa Cruz); anti-Smad4 (sc-7966, Santa Cruz); anti-myc tag (2276, Cell Signaling); anti V5 tag (R960-25, Invitrogen); anti-c-FLIP (ALX-804-127, Enzo Life Sciences); anti-c-Jun (9165, Cell Signalling); anti-p63 (Ab110038, Abcam); anti a-Tubulin (T6074, Sigma) and anti-Actin (sc-1616, Santa Cruz Biotechnology). Reactive bands were visualized with ECL plus reagent (Amersham). Relative expression was quantified with Image Quant TL software (GE Healthcare)

Immunohistochemistry {#S13}
--------------------

Formalin-fixed paraffin-embedded (FFPE) mouse tissues were cut into 3-μm tissue sections, and antigen retrieval was performed in 10mM, pH 6.0 citric acid (for Usp9x and E-cadherin) or 10mM, pH 8.0 EDTA (for Smad4). Endogenous peroxidases were quenched in 3% H~2~O~2~/PBS for 20 minutes. Signal detection for immunohistochemistry was accomplished with biotinylated secondary antibodies (Vector Laboratories, Burlingame, CA) using the Elite Vectastain ABC kit and peroxidase substrate DAB kit (Vector Laboratories, Burlingame, CA). Primary antibodies used were anti-Usp9x, 1:200 (A301-351A, Bethyl); E-cadherin, 1:200 (610182, BD) and anti-Smad4, 1:100 (sc-7966, Santa Cruz). Slides were counterstained with hematoxylin.

Clinical patient samples immunohistochemistry and analysis {#S14}
----------------------------------------------------------

Tissue microarrays (n=404) were prepared from patient samples obtained after appropriate informed consent in Dresden (Institute of Pathology, University Hospital Dresden), Regensburg (Institute of Pathology, University Hospital Regensburg) and Jena (Institute of Pathology, University Hospital Jena). Informed consent was obtained for each patient, following review by the human ethics committee Ethikkommission an der Technischen Universität Dresden The PDA tumor samples were collected from 1993--2009, and the majority of the patients (65%) did not undergo adjuvant chemotherapy. Those that did undergo adjuvant therapy (35%) were chiefly treated with 5FU or gemcitabine-based regimens, but in this subgroup there was no significant increase in patient survival. The median survival times of patients following surgery from each center were indistinguishable. Immunohistochemistry was performed on 5 μm sections that were prepared using silanized slides (Menzel Gläser, Braunschweig, Germany). Staining was performed with the Benchmark System (Ventana, Illkirch, France), using rabbit anti-USP9X antibody, 1:200 (A301-351A, Bethyl) and anti-ITCH, 1:200 (611198, BD); and the protocol UltraView HRP, with the CC1 modified protocol as pretreatment. Slides were counterstained with hematoxylin. Staining intensities were scored as absent (0), weak (1), medium (2) and strong (3). For further analysis the staining intensities were grouped as negative (0) and positive (1--3). The Cox regression model assumption of proportional hazard was tested using a plot of the cumulative hazards function.

A second cohort of patient samples was obtained from the Gastrointestinal Cancer Rapid Medical Donation Program in the Department of Pathology at Johns Hopkins Hospital, USA. Use of all human tissue samples from resection specimens and autopsy participants was approved by Johns Hopkins Institutional Review Board, and obtained after informed consent. All samples were collected within 12 hours postmortem and formalin fixed before paraffin embedding. 5 μm sections were cut from matched primary and metastasis samples onto glass slides. Slides were first incubated in Dako Target Retrieval Solution for antigen retrieval. Slides were then incubated with rabbit anti-USP9X antibody, 1:1000 (ab26334, Abcam) or 1:200 (NBP1-48321, Novus Bilogicals), and anti-SMAD4 as previously described^[@R38]^. Signal detection for immunohistochemistry was accomplished with Dako LSAB+System-HRP. Slides were counterstained with hematoxylin.

An additional cohort of pancreatic cancer resection samples was prospectively acquired through the Australian Pancreatic Cancer Network and the Australian Pancreatic Cancer Genome Initiative (<http://www.pancreaticcancer.net.au/apgi>). Consent was obtained for genomic sequencing through the Australian Pancreatic Cancer Genome Initiative (APGI) for each individual patient following approval from Human Research Ethics Committees (HREC) at participating sites (Sydney South West Area Health Service HREC Western Zone, 2006/054; Sydney Local Health Network HREC RPA Zone, X11-0220 and North Sydney Central Coast Health, Harbour HREC, 0612-251M). We extracted RNA from tumour samples using the Qiagen Allprep^®^ Kit (Qiagen, Valencia, CA) in accordance with the manufacturer's instructions, assayed for quality on an Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA), and subsequently hybridized to Illumina Human HT-12 V4 microarrays. Raw idat files were processed using *IlluminaGeneExpressionIdatReader* (Cowley *et al.* manuscript in preparation). Following array quality control, these data were vs.t transformed, and then robust spline normalized, using the *lumi* R/Bioconductor package. For the ICGC-APGI cohort, we assumed a proportional hazard: that the probability of death is the same for those censored as for those remaining on study.

For the TMA and expression array cohorts, median survival was estimated using the Kaplan-Meier method and the difference was tested using the log-rank test. P-values of less than 0.05 were considered statistically significant. For the TMA cohort, as few parameters were significant in univariate analysis, all were initially considered for Cox Proportional Hazard multivariate analysis in a backward elimination model, and assessed with the SPSS18 Software (IBM, Ehningen, Germany) with overall survival used as the primary endpoint. For the ICGC-APGI cohort, clinico-pathologic variables analyzed with a P-value of less than 0.25 on log-rank test were entered into Cox Proportional Hazard multivariate analysis and the model was resolved using backward elimination. Statistical analysis was performed using StatView 5.0 Software (Abacus Systems, Berkeley, CA, USA). Disease-specific survival was used as the primary endpoint.
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![Transposon mutagenesis accelerates murine PDA and targets Usp9x\
**a**, Increased mortality of KCTSB13 mice compared to KC cohort (containing KCT, KCSB13 and KC mice) (172 vs. 257 days, p\<0.001; long-rank test). Wild-type (WT) cohort is comprised of KTSB13 and CTSB13 mice. **b--c,** Invasive cystic neoplasm (**b**), and mPDA (**c**) in KCTSB13 mice. Scale bar: 100μm. **d**, *Usp9x* is the major CIS in KCTSB13 PDA tumors (X-axis denotes genome, Y-axis −log P-value), with bidirectional insertions. (+) parallel to *Usp9x* expression, (−) antiparallel. **e**, *Usp9x Exon 2-T2/Onc* chimeric mRNA in SB13 tumors. **f--g**, Usp9x protein expression in normal pancreatic ducts (arrow) (**f**), but not in neoplastic cells (**g**) (arrows) in SB13 PDA harboring Usp9x insertions. Scale bar: 100μm.](nihms368884f1){#F1}

![Usp9x regulates PDA cellular transformation and Itch\
**a--b,** Usp9x knock-down promotes anchorage-independent growth in three mPDA cell lines (**a**), and decreases anoikis denoted by cleaved caspase 3 (CC3) (**b**). The mean and s.e.m. of one representative experiment performed in triplicate are shown in (**a**) (\*\*\*, p\<0.001; Mann Whitney test). (S: Scramble; U: Usp9x). **c,** Usp9x knock-down decreases Itch but not Ask1 or Mcl1. Changes in Itch are more evident in suspension cultures, and the slower migrating band has the expected mobility of mono-ubiquitinated Itch. **d,** Ectopic Itch induces anoikis. (B: pBabe-neo; I: pBabe-neo-myc-Itch).](nihms368884f2){#F2}

![*USP9X* loss promotes PDA\
**a--c,** Decreased USP9X expression correlates with shortened survival in Australian post-surgical cohort (**a**) (8.7 vs. 18.4 months, p=0.0076; log-rank test), increased metastatic burden in American autopsy series (**b**) (54% vs. 19%, p=0.0212; Fisher's exact test), and diminished survival in German post-surgical cohort (**c**) (11.1 vs. 16.1 months, p=0.037; log-rank test). **d,** Trichostatin A (TSA, Red) and 5-Aza-2′-deoxycytidine (AZA, Blue) modestly increase *USP9X* mRNA expression. The mean and s.e.m. of one representative experiment performed in triplicate are shown. **e,** *Usp9x* deletion promotes mPanIN progression in KCU mice (p\<0.0001; Fisher's exact test). **f,** Representative normal pancreas (CU), mPanIN1 (KC), mPanIN3 (KCU) and microinvasive mPDA (KCU, arrow, circled). Scale bar: 100μm.](nihms368884f3){#F3}

###### Top 20 candidate genes that cooperate with *Kras^G12D^* to promote mPDA in KCTSB13 mice

CISs were scored by tumor frequency with the narrowest 15K kernel spatial distribution of insertion sites. Chr: chromosome; N: number of tumors from which the CIS was found; I, total number of insertions of the CIS in the indicated tumors.

  Gene            Chr   CIS Peak Location   CIS Height   N     I     Mutation in humans
  --------------- ----- ------------------- ------------ ----- ----- --------------------
  Usp9x           X     12691773            158.1266     101   341   
  Pten            19    32872602            64.5204      61    96    
  Fndc3b          3     27562591            13.7096      55    67    
  Setd5           6     113057997           35.6176      52    71    
  Arfip1\|Fbxw7   3     84769635            21.6666      48    80    Yes^[@R5]^
  Fam193a         5     34705809            24.3555      45    78    
  Ctnna1          18    35342868            20.2017      45    50    
  Magi1           6     93859940            13.3715      43    57    
  Mkln1           6     31414109            16.5263      41    53    
  Pum1            4     130288478           12.7948      41    46    Yes^[@R5]^
  Farp1           14    121587858           9.407        39    47    
  Foxp1           6     98921646            19.5831      38    60    
  Arid1a          4     133268936           32.1628      38    47    Yes^[@R5]^
  Acvr1b          15    101024934           31.1752      38    47    Yes^[@R15]^
  Map4k3          17    81109860            13.2385      38    45    Yes^[@R5]^
  Stag2           X     39535994            16.8613      37    48    
  Mll5            5     22982314            16.0001      37    43    Yes^[@R5]^
  Atxn2\|Sh2b3    5     122267680           12.3174      37    41    
  Arhgap5         12    53644560            37.416       35    61    
  Gsk3b           16    38106972            21.79        35    43    
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